Back to Search
Start Over
Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study
- Source :
- Dipòsit Digital de la UB, Universidad de Barcelona, International Ophthalmology, INTERNATIONAL OPHTHALMOLOGY, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Publication Year :
- 2021
- Publisher :
- Springer Nature, 2021.
-
Abstract
- Purpose To describe and evaluate the main direct health costs, in routine clinical practice, of age-related macular degeneration (AMD) patients, from hospital perspective, in Spain. Methods Retrospective, multicenter, and observational study conducted on five third-level Spanish hospitals, between December 2018 and December 2019. The study included patients who were diagnosed of AMD before December 2018. Direct healthcare costs were obtained from a Spanish database. Study variables included demographic and clinical variables, and resources, such as treatment, diagnostic tests, medical examination, and surgery. Among the 1414 screened AMD patients, 1164 patients were included. In the overall study patients, the total cost was €5,386,511.0, with a mean cost per patient of €4627.6 ± 2383.9. The largest cost items were diagnostic examinations (€2.832.902,0) and vascular endothelial growth factor inhibitors (anti-VEGF) treatment (€2.038.257,2). Bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 328 (28.2%), and aflibercept to 626 (53.8%); 115 (10.7%) patients received two anti-VEGF treatments, while 90 (7.7%) did not receive any. Over the course of the study, a total of 6,057 anti-VEGF injections were administered, with a mean (95% confidence interval) of 4.8 (4.4–5.2) injections per patient. Regarding safety, 29 patients experience injection-related adverse events, among them 12 patients had cataract and 11 ones elevated intraocular pressure (IOP). The incidence of endophthalmitis was 0.5% (6/1164). Conclusions AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.
- Subjects :
- Vascular Endothelial Growth Factor A
medicine.medical_specialty
Bevacizumab
genetic structures
Recombinant Fusion Proteins
Visual Acuity
Angiogenesis Inhibitors
Economic burden
03 medical and health sciences
Macular Degeneration
0302 clinical medicine
Endophthalmitis
Cost of Illness
Internal medicine
Ranibizumab
medicine
Medical economics
Humans
030212 general & internal medicine
Adverse effect
Economia de la salut
Aflibercept
Retrospective Studies
Original Paper
business.industry
Incidence (epidemiology)
Age-related macular degeneration
Macular degeneration
Ophthalmopathies
medicine.disease
Vascular endothelial growth factor inhibitors
VEGF
Ophthalmology
Receptors, Vascular Endothelial Growth Factor
Intravitreal Injections
030221 ophthalmology & optometry
Observational study
business
Health economics
Oftalmopaties
medicine.drug
Subjects
Details
- ISSN :
- 01655701
- Database :
- OpenAIRE
- Journal :
- Dipòsit Digital de la UB, Universidad de Barcelona, International Ophthalmology, INTERNATIONAL OPHTHALMOLOGY, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Accession number :
- edsair.doi.dedup.....edb718ac6a31bd776afcded4e7b9341e